Leveraging Genomic Databases to Identify Missense Variants and Therapeutic Targets for Atopic Dermatitis

ผู้แต่ง

DOI:

https://doi.org/10.12982/BSCM.2026.50

คำสำคัญ:

atopic dermatitis, bioinformatics, GWAS, IL6R, TESPA1

บทคัดย่อ

Objective  Atopic dermatitis (AD) is a complex inflammatory skin disorder with a strong genetic component. Identifying missense variants with functional relevance is essential for understanding disease mechanisms and informing therapeutic development. This study identified functionally relevant SNPs for AD using integrated genomic and bioinformatics analyses.

Methods  We screened 180 AD-associated SNPs from the GWAS Catalog
and filtered missense variants with genome-wide significance. Functional impact was assessed using PolyPhen-2 and Sorting Intolerant From Tolerant (SIFT). Population allele frequencies were extracted from the 1000 Genomes Project, tissue expression profiles from the GTEx Portal, and drug–gene interactions from DGIdb.

Results Two prioritized missense variants were identified: rs2228145 in IL6R, a common benign variant that modulates IL-6 signaling, and rs183884396 in TESPA1, a rare variant predicted to be damaging and
enriched in European populations. TESPA1 showed minimal expression in healthy skin but substantial expression in immune-relevant tissues, suggesting an indirect immunoregulatory role in AD. IL6R demonstrated broad immune-tissue expression and multiple interactions with approved anti-inflammatory drugs, underscoring its therapeutic relevance.

Conclusion By integrating genomic, functional, and pharmacological data, this study highlighted TESPA1 as a biologically plausible yet understudied immunoregulatory gene and IL6R as a clinically actionable target in AD. These computational findings are hypothesis-generating and warrant experimental validation to elucidate variant-specific mechanisms. Importantly, the identification of IL6R-targeting drugs and the ancestry-specific
nature of TESPA1 variation provides a foundation for future precision- medicine approaches in AD. 

เอกสารอ้างอิง

Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2020;8:91-101.

Langan SM, Mulick AR, Rutter CE, Silverwood RJ, Asher I, García-Marcos L, et al. Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study. Clin Exp Allergy. 2023;53:337-52.

Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019; 139:583-90.

Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990-2017. Br J Dermatol. 2021;184:304-9.

Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol. 2014;41:213-20.

Wirawan Adikusuma, Eko Mugiyanto, Lalu Muhammad Irham, Firdayani Firdayani, Shelvi Listiana, Muthia Rahayu Iresha, Ayu Masyita, Maulida Mazaya, Riza Alfian. Bioinformatics insights into transcriptomic biomarkers for atopic dermatitis. J Res Pharm. 2025;29:892-902.

Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115-S23.

Liang Y, Chang C, Lu Q. The genetics and epigenetics of atopic dermatitis-filaggrin and other polymorphisms. Clin Rev Allergy Immunol. 2016;51:315-28.

Sliz E, Huilaja L, Pasanen A, Laisk T, Reimann E, Magi R, et al. Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis. J Allergy Clin Immunol. 2022;149:1105-12 e9.

Devuyst O. The 1000 genomes project: welcome to a new world. Perit Dial Int. 2015;35:676-7.

Dayem Ullah AZ, Oscanoa J, Wang J, Nagano A, Lemoine NR, Chelala C. SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. Nucleic Acids Res. 2018;46(W1):W109-W13.

Oscanoa J, Sivapalan L, Gadaleta E, Dayem Ullah AZ, Lemoine NR, Chelala C. SNPnexus: a web server for functional annotation of human genome sequence variation (2020 update). Nucleic Acids Res. 2020; 48(W1):W185-W92.

Coorens THH, Guillaumet-Adkins A, Kovner R, Linn RL, Roberts VHJ, Sule A, et al. The human and non-human primate developmental GTEx projects. Nature. 2025;637(8046):557-64.

Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005-D12.

Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science. 2023;381(6664):eadg7492. PubMed PMID: 37733863

Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7: Unit7 20.

Vaser R, Adusumalli S, Leng SN, Sikic M, Ng PC. SIFT missense predictions for genomes. Nat Protoc. 2016; 11:1-9.

Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68-74.

Belsare S, Levy-Sakin M, Mostovoy Y, Durinck S, Chaudhuri S, Xiao M, et al. Evaluating the quality of the 1000 genomes project data. BMC Genomics. 2019;20(1):620. PubMed PMID: 31416423

Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021;49(D1): D1144-D51.

Kuru N, Dereli O, Akkoyun E, Bircan A, Tastan O, Adebali O. PHACT: phylogeny-aware computing of tolerance for missense mutations. Mol Biol Evol. 2022; 39(6):msac114 PubMed PMID: 35639618

Ferreira MA, Matheson MC, Duffy DL, Marks GB, Hui J, Le Souef P, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. 2011; 378(9795):1006-14.

Hawkins GA, Robinson MB, Hastie AT, Li X, Li H, Moore WC, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol. 2012;130:510-5 e1.

Esparza-Gordillo J, Schaarschmidt H, Liang L, Cookson W, Bauerfeind A, Lee-Kirsch MA, et al. A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. J Allergy Clin Immunol. 2013;132:371-7.

Zhao SS, Yiu ZZN. Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis. J Allergy Clin Immunol. 2024;154:666-9.

Adikusuma W, Irham LM, Chou WH, Wong HS, Mugiyanto E, Ting J, et al. Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Front Immunol. 2021;12:724277.

Pasanen A, Sliz E, Huilaja L, FinnGen, Estonian Biobank Research T, Reimann E, et al. Identifying atopic dermatitis risk loci in 1,094,060 individuals with subanalysis of disease severity and onset. J Invest Dermatol. 2024;144:2417-25.

Oliva M, Sarkar MK, March ME, Saeidian AH, Mentch FD, Hsieh CL, et al. Integration of GWAS, QTLs and keratinocyte functional assays reveals molecular mechanisms of atopic dermatitis. Nat Commun. 2025; 16(1):3101. PubMed PMID: 40164604

Marenholz I, Arnau-Soler A, Rosillo-Salazar OD, Lee YA. New insights from genetic studies of eczema. Med Genet. 2023;35:33-45.

ดาวน์โหลด

เผยแพร่แล้ว

2026-10-14

รูปแบบการอ้างอิง

1.
Nurullita Santri I, Muhammad Irham L, Pranata S, Firdayani F, Vincent Abero Phiri Y, Alfian R, Dani Satria R, Adikusuma W. Leveraging Genomic Databases to Identify Missense Variants and Therapeutic Targets for Atopic Dermatitis. BSCM [อินเทอร์เน็ต]. 14 ตุลาคาม 2026 [อ้างถึง 15 ตุลาคาม 2026];65(4). available at: https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/282211

ฉบับ

ประเภทบทความ

Original Article